Please use this identifier to cite or link to this item:
https://scholarhub.balamand.edu.lb/handle/uob/5886
Title: | Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review | Authors: | Wanchoo, Rimda Karam, Sabine Uppal, Nupur N Barta, Valerie S Deray, Gilbert Devoe, Craig Launay-Vacher, Vincent Jhaveri, Kenar D |
Affiliations: | Faculty of Medicine | Keywords: | Acute interstitial nephritis Ipilimumab Targeted therapies Nivolumab Onconephrology Pembrolizumab Renal failure |
Issue Date: | 2017 | Publisher: | National Library of Medicine | Part of: | American Journal of Nephrology | Volume: | 45 | Issue: | 2 | Start page: | 160 | End page: | 169 | Abstract: | Cancer immunotherapy, such as anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and anti-programmed death 1 (PD-1), has revolutionized the treatment of malignancies by engaging the patient's own immune system against the tumor rather than targeting the cancer directly. These therapies have demonstrated a significant benefit in the treatment of melanomas and other cancers. |
URI: | https://scholarhub.balamand.edu.lb/handle/uob/5886 | ISSN: | 02508095 | DOI: | 10.1159/000455014 | Open URL: | Link to full text | Type: | Journal Article |
Appears in Collections: | Faculty of Medicine |
Show full item record
SCOPUSTM
Citations
284
checked on Nov 23, 2024
Record view(s)
38
checked on Nov 23, 2024
Google ScholarTM
Check
Altmetric
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.